-
1 Comment
BioNTech SE is currently in a long term uptrend where the price is trading 57.6% above its 200 day moving average.
From a valuation standpoint, the stock is 96.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 49.5.
BioNTech SE's total revenue rose by 1134.3% to $345M since the same quarter in the previous year.
Its net income has increased by 730.2% to $367M since the same quarter in the previous year.
Finally, its free cash flow grew by 406.1% to $224M since the same quarter in the previous year.
Based on the above factors, BioNTech SE gets an overall score of 5/5.
Sector | Healthcare |
---|---|
Industry | Biotechnology |
ISIN | US09075V1026 |
CurrencyCode | EUR |
Exchange | F |
Dividend Yield | 0.0% |
---|---|
Target Price | 334.89 |
Beta | 0.24 |
PE Ratio | 3.12 |
Market Cap | 28B |
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 22UA.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024